Literature DB >> 21382893

Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial.

Jagmeet P Singh1, Helmut U Klein, David T Huang, Sven Reek, Malte Kuniss, Aurelio Quesada, Alon Barsheshet, David Cannom, Ilan Goldenberg, Scott McNitt, James P Daubert, Wojciech Zareba, Arthur J Moss.   

Abstract

BACKGROUND: An important determinant of successful cardiac resynchronization therapy for heart failure is the position of the left ventricular (LV) pacing lead. The aim of this study was to analyze the impact of the LV lead position on outcome in patients randomized to cardiac resynchronization-defibrillation in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) study. METHODS AND
RESULTS: The location of the LV lead was assessed by means of coronary venograms and chest x-rays recorded at the time of device implantation. The LV lead location was classified along the short axis into an anterior, lateral, or posterior position and along the long axis into a basal, midventricular, or apical region. The primary end point of MADIT-CRT was heart failure (HF) hospitalization or death, whichever came first. The LV lead position was assessed in 799 patients, (55% patients ≥65 years of age, 26% female, 10% LV ejection fraction ≤25%, 55% ischemic cardiomyopathy, and 71% left bundle-branch block) with a follow-up of 29±11 months. The extent of cardiac resynchronization therapy benefit was similar for leads in the anterior, lateral, or posterior position (P=0.652). The apical lead location compared with leads located in the nonapical position (basal or midventricular region) was associated with a significantly increased risk for heart failure/death (hazard ratio=1.72; 95% confidence interval, 1.09 to 2.71; P=0.019) after adjustment for the clinical covariates. The apical lead position was also associated with an increased risk for death (hazard ratio=2.91; 95% confidence interval, 1.42 to 5.97; P=0.004).
CONCLUSION: LV leads positioned in the apical region were associated with an unfavorable outcome, suggesting that this lead location should be avoided in cardiac resynchronization therapy. Clinical Trial Registration- URL: http://clinicaltrials.gov. Unique identifier: NCT00180271.

Entities:  

Mesh:

Year:  2011        PMID: 21382893     DOI: 10.1161/CIRCULATIONAHA.110.000646

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  121 in total

Review 1.  Updates in Cardiac Resynchronization Therapy for Chronic Heart Failure: Review of Multisite Pacing.

Authors:  Antonios P Antoniadis; Ben Sieniewicz; Justin Gould; Bradley Porter; Jessica Webb; Simon Claridge; Jonathan M Behar; Christopher Aldo Rinaldi
Journal:  Curr Heart Fail Rep       Date:  2017-10

Review 2.  Multimodality imaging in interventional cardiology.

Authors:  Bas L van der Hoeven; Martin J Schalij; Victoria Delgado
Journal:  Nat Rev Cardiol       Date:  2012-02-14       Impact factor: 32.419

3.  Elimination of phrenic nerve stimulation occurring during CRT: follow-up in patients implanted with a novel quadripolar pacing lead.

Authors:  Paresh A Mehta; Anoop K Shetty; Mark Squirrel; Julian Bostock; C Aldo Rinaldi
Journal:  J Interv Card Electrophysiol       Date:  2011-07-21       Impact factor: 1.900

Review 4.  Nuclear Image-Guided Approaches for Cardiac Resynchronization Therapy (CRT).

Authors:  Weihua Zhou; Ernest V Garcia
Journal:  Curr Cardiol Rep       Date:  2016-01       Impact factor: 2.931

5.  Periprocedural management of cardiac resynchronization therapy.

Authors:  John Rickard; Niraj Varma
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-04

Review 6.  How to improve outcomes with cardiac resynchronisation therapy: importance of lead positioning.

Authors:  Peter J Cowburn; Christophe Leclercq
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

7.  Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes.

Authors:  Robert K Altman; Kimberly A Parks; Christopher L Schlett; Mary Orencole; Mi-Young Park; Quynh A Truong; Peerawut Deeprasertkul; Stephanie A Moore; Conor D Barrett; Gregory D Lewis; Saumya Das; Gaurav A Upadhyay; E Kevin Heist; Michael H Picard; Jagmeet P Singh
Journal:  Eur Heart J       Date:  2012-05-21       Impact factor: 29.983

Review 8.  Targeting left ventricular lead placement to improve cardiac resynchronization therapy outcomes.

Authors:  Jeffrey Liu; Evan Adelstein; Samir Saba
Journal:  Curr Cardiol Rep       Date:  2013-08       Impact factor: 2.931

Review 9.  Devices in the management of advanced, chronic heart failure.

Authors:  William T Abraham; Sakima A Smith
Journal:  Nat Rev Cardiol       Date:  2012-12-11       Impact factor: 32.419

10.  The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy.

Authors:  David D Daly; Anbukarasi Maran; J Madison Hyer; Frederick Funke; Ashley Waring; Frank A Cuoco; J Lacy Sturdivant; Robert B Leman; Michael R Gold
Journal:  Pacing Clin Electrophysiol       Date:  2016-06-07       Impact factor: 1.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.